11. Impaired cardiac function or clinically significant cardiac diseases, including any one of the following: 11.1. History or presence of sustained ventricular tachyarrhythmia. (Patients with a history of atrial arrhythmia are eligible but should be discussed with Novartis prior to enrollment). 11.2 Any history of ventricular fibrillation or torsade de pointes. 11.3. Bradycardia defined as HR< 50 bpm. Patients with pacemakers are eligible if HR >/= 50 bpm. 11.4. Screening ECG with a QTc > 470 msec. 11.5. Right bundle branch block + left anterior hemiblock (bifascicular block). 11.6. Myocardial infarction or unstable angina </= 12 months prior to starting study drug. 11.7. Other clinically significant heart disease (e.g., CHF NY Heart Association class III or IV , uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen).